A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
PHASE1CompletedINTERVENTIONAL
Enrollment
33
Participants
Timeline
Start Date
November 5, 2015
Primary Completion Date
March 31, 2020
Study Completion Date
March 26, 2020
Conditions
Advanced Solid TumorsMultiple Myeloma
Interventions
DRUG
ONC-201
Trial Locations (1)
19111-2497
Fox Chase Cancer Center - Philadelphia, Philadelphia
All Listed Sponsors
lead
Fox Chase Cancer Center
OTHER
NCT02609230 - A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | Biotech Hunter | Biotech Hunter